The company launched the IPO after doubling revenue in 2024, driven by increased oil production from well acquisitions worth ...

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Pimco, one of the world’s largest bond managers, owns 354 million Class A shares of Venture Global (VG), the natural-gas exporter that went ...

Shares in Venture Global are expected to make their debut on the New York Stock Exchange after the company raised $1.75 ...

Bond manager’s $7 billion stake in Venture Global latest sign that traditional asset managers are making inroads investing in ...